Transgenic mosquitoes resistant to malaria parasites are being developed to test the hypothesis that they may be used to control disease transmission. We have developed an effector portion of an antiparasite gene that can be used to test malaria resistance in transgenic mosquitoes. Mouse monoclonal antibodies that recognize the circumsporozoite protein of Plasmodium gallinaceum can block sporozoite invasion of Aedes aegypti salivary glands. An anti-circumsporozoite monoclonal antibody, N2H6D5, whose corresponding heavy-and light-chain gene variable regions were engineered as a single-chain antibody construct, binds to P. gallinaceum sporozoites and prevents infection of Ae. aegypti salivary glands when expressed from a Sindbis virus. Mean intensities of sporozoite infections of salivary glands in mosquitoes expressing N2scFv were reduced as much as 99.9% when compared to controls.
INTRODUCTION
Malaria is a mosquito-borne disease caused by protozoan parasites in the genus Plasmodium. It exacts a tremendous toll on humans causing more than two million deaths annually. 1 Previous efforts to control malaria have focused on prophylactic and therapeutic drugs to prevent infection and disease in humans 2 and mosquito control to prevent transmission of pathogens. 3 These approaches have been effective in many areas of the world, but have failed to eradicate the disease. Furthermore, some regions of Africa benefited only modestly from malaria control practices even at the peak of their success. Recently, while efforts to develop malaria vaccines have intensified, 4 the increases in resistance of parasites to drugs and mosquitoes to insecticides have qualified malaria as an emerging disease in areas where it once was controlled. 5, 6 The threat of malaria has promoted research to develop new control strategies exploiting vector genetics and physiology. 7, 8 One proposed approach is to control transmission by modifying the competence of a mosquito to support the development of parasites. 9 The hypothesis of this approach is that the introduction of an antiparasite gene at a sufficient frequency into a population of vector mosquitoes should result in less transmission, and therefore less disease. Efforts to test this hypothesis focus on three research areas: 1) the development in the laboratory of parasite-resistant mosquito strains, 2) discovery of methods for introducing antiparasite genes into populations, and 3) study of target populations so that the behavior and efficacy of introduced genes can be predicted and monitored. 9 We are working with Aedes aegypti mosquitoes and the avian malaria parasite, Plasmodium gallinaceum, as an experimental model in order to develop and test many of the basic methodologies that will be applied later to the human malaria parasites and their anopheline vectors. We isolated and characterized mosquito genes whose promoters can be used to express an antiparasite coding region. 10 We also developed stable transformation technology that would allow the integration of antiparasite genes into the mosquito germline. 11, 12 Here we report the development of an effective antiparasite gene.
Malaria parasites are ingested when mosquitoes feed on an infected vertebrate host. Gametocytes produced in the host develop into male and female gametes in the mosquito midgut, and following fertilization, develop from a zygote to a motile ookinete that traverses the single-cell layer of the midgut and develops on the basal surface of the epithelial cells. The developing parasite forms an oocyst in which several thousand sporozoites are produced. The sporozoites break free from oocysts, make their way through the hemolymph, the fluid medium of the open circulatory system of the insect, and invade the salivary glands. They then are inoculated into a new vertebrate host during the next blood meal. We have focused on the sporozoites as the targets of an antiparasite gene at the time that they transit the hemolymph from the midgut to the salivary glands.
The molecular target on the sporozoite is the circumsporozoite protein (CSP), the predominant surface antigen of this parasite stage and one of a number of putative parasite ligands that may mediate recognition and invasion of the salivary glands. 13 Mouse monoclonal antibodies (MAbs) reactive to the CSP of P. gallinaceum block sporozoite invasion of salivary glands, 14 as well as prevent the infection of vertebrate host cells. 15, 16 We engineered molecularly a singlechain antibody (scFv), designated N2scFv, that is based on an anti-CSP MAb, N2H6D5. 17 Expression in vivo of N2scFv by a Sindbis virus vector 18, 19 results in a marked reduction of the mean intensity of sporozoite infections of mosquito salivary glands.
MATERIALS AND METHODS
Mosquito rearing and maintenance of the parasite lifecycle. The RED strain of Ae. aegypti is highly-susceptible to P. gallinaceum, 20 and was used in all experiments. Mosquitoes were reared using standard laboratory procedures. 21 An aliquot of frozen chicken blood infected with P. gallinaceum strain 8A 22 was obtained from B. Christensen (University of Wisconsin, Madison, WI). This sample was used to inoculate and establish initial infections in chickens. All subsequent infections of chickens and mosquitoes were accomplished by having mosquitoes feed on the chickens. The maintenance and care of experimental animals complies with National Institutes of Health guidelines for the humane use of laboratory animals.
Construction of single-chain antibody genes. Mouse hybridoma cells were cultured in RPMI 1640 (GIBCO BRL, Rockville, MD) supplemented with 10% fetal calf serum. To construct the antimalarial scFv gene, total RNA was purified from the N2H6D5 hybridoma cell line 17 using Trizol (GIB-CO BRL) and mRNA prepared using the Quick Prep Micro mRNA Purification Kit (Amersham Pharmacia Biotech, Piscataway, NJ). The mRNA was quantified and an aliquot was used in a commercial gene amplification protocol optimized for scFv gene production (Amersham Pharmacia Biotech). Briefly, oligonucleotide primers based on conserved nucleotide sequences in the variable regions of the heavy-chain (V H ) and light-chain (V L ) immunoglobulin genes were used to synthesize the first strands of corresponding cDNA molecules using reverse transcriptase and dNTPs. A second primer complementary to a nucleotide sequence specific to the V H or V L cDNA was added to the appropriate reaction, and gene amplification was used to produce a large amount of the specific fragment. An oligonucleotide linker region (L) with sequence at its 5Ј-end complementary to the V H fragment and at its 3Ј-end complementary to the V L fragment, and containing nucleotides encoding three repeats of Gly 4 Ser, was used to assemble a 5Ј-V H -L-V L -3Ј fragment, which then was amplified quantitatively. The final product, N2scFv, was cloned into the pCANTAB-5E (Pharmacia Biotech) plasmid for further analysis. This plasmid adds an epitope tag (E-tag) to the recombinant protein that permits rapid column purification and identification of the recombinant protein. Following transformation of Eschericia coli (strain TG1) and selective plating, candidate clones were screened for inserts and sequenced. Similar procedures were used to clone a negative control reagent, 4G2scFv, from a hybridoma line, 4G2, that expresses a MAb that binds to the E glycoprotein of dengue virus. 23, 24 Gene amplification procedures were used to clone the N2scFv/E-tag fusion gene into a baculovirus system (pFast Bac Dual Expression vector, GIBCO BRL), modified to contain an enhanced green fluorescent protein (EGFP) marker gene, pFBG3 (Hice R and Atkinson P, unpublished data). Again, the integrity of all constructs was verified by primary sequence determination of the relevant DNA. Baculovirusexpressed recombinant protein was produced according to the instructions of the manufacturer.
Protein detection and indirect immunofluorescence analysis. Proteins analyzed in immunoblot assays were solubilized in Laemmli buffer, 25 resolved in SDS-PAGE gels, and then stained either with Coomassie Blue R or transferred to nitrocellulose membranes. The membranes containing the transferred proteins were incubated in 1:100 dilutions of commercial primary antibodies that recognize the E-tag (Amersham Pharmacia Biotech) or goat antimouse IgG (Jackson Immunoresearch Laboratories, Inc., West Grove, PA). Secondary antibodies conjugated with peroxidase and the enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech) were used to visualize the resolved proteins.
Plasmodium gallinaceum sporozoites analyzed by indirect immunofluorescence were recovered from the hemolymph of Sindbis virus-infected adult mosquitoes 10 days after a blood meal on parasite-infected chickens. Parasites in the hemolymph were released by gently separating the abdomen from the thorax in a drop (ϳ75 L) of Aedes saline (20 mM HEPES, 150 mM NaCl, 3.3 mM KCl, 2.2 mM MgCl 2 , 2.2 mM CaCl 2 , 1.8 mM NaHCO 3 , pH 7.0). The diluted hemolymph was transferred to a microcentrifuge tube using a mechanical pipette. Hemolymph preparations from a number of mosquitoes were pooled, and sporozoites were pelleted in a microcentrifuge at low speed. The parasites were resuspended in Aedes saline, pelleted again by centrifugation, resuspended in 50 L of Aedes saline and an aliquot quantified using a hemocytometer. One thousand sporozoites each were placed in wells of multispot antigen slides and kept at Ϫ20ЊC until use. The slides were fixed with a 4% formaldehyde solution in 10 mM phosphate buffer, pH 7.3, containing 0.13 M NaCl (PBS) for 30 min at room temperature (RT). After careful washing of the wells with drops of PBS containing 0.075% NP40, the slides were incubated for 20 min at RT with 1% bovine serum albumin (PBS/BSA). Slides were incubated for one hour at RT with the E-tag antibody diluted 1:100 in PBS/NP40. The slides were washed with PBS/BSA and incubated for 30 min at RT with a 1:50 dilution of fluorescein isothiocyanate (FITC) labeled goat anti-mouse IgG. After the final wash, the slides were dried, mounted in Fluoromount (Southern Biotechnology Associates, Birmingham, AL), and examined using UV microscopy.
Sindbis virus cloning and expression of scFv in mosquitoes. A 72 base pair (bp) region (nt ϩ57 to ϩ128) of the Maltase-like I (Mal I) gene 26 encoding the translational initiation codon and the 22 amino acids of the putative secretory signal peptide was added to the 5Ј-end of the N2scFv cDNA to facilitate secretion into the hemolymph of the virally-expressed protein. The addition of these sequences was performed in a two-step gene amplification reaction using the scFv cDNA cloned in the pCANTAB-5E plasmid as a template and the following oligonucleotide primers: Primer 1) 5Ј-ACTAACCACCGGGTTGGACTGGTGGGAAGCCC-AGGTGCAACTGCAGGAGTC-3Ј, Primer 2) 5Ј-GCTCTA-GACTATGCGGCACGCGG-3Ј, and Primer 3) 5Ј-CGTC-TAGAATGAAGATCTTTGTTCCACTTCTAAGCTT-CCTCCTAGCAGGACTAAC-3Ј. Primers 1 and 2 were used to add the 3Ј-end of the Mal I gene fragment to the N2ScFv construct and were designed to retain the E-tag at the 3Ј-end of the final amplification product. Following amplification, the product was purified over a G25 spin column. A second gene amplification was performed with Primers 2 and 3, which added an Xba I restriction endonuclease site along with the 5Ј-end of the Mal I sequence. The amplification product was purified over a G25 column and cloned into the plasmid, pCR2.1 (Invitrogen, Carlsbad, CA). Dra I was used to remove an internal fragment in the plasmid, and following religation, Xba 1 was used to recover a fragment containing the expression construct. This fragment was cloned into the Sindbis virus expression vector, TE/3Ј2J 19 to produce SinN2scFv. The primary sequence of each construct was determined before further use.
A similar gene amplification protocol was used to add the Mal I leader peptide sequences to the 4G2scFv construct. The following specific primers were used for the amplification in addition to Primers 2 and 3 above: Primer 4) 5Ј-← and prepared for gel electrophoresis. Whole proteins in homogenates were resolved in gels and visualized by staining with Coomasie Blue R (left). An identical gel was prepared and blotted to a filter (right). The filter was incubated in the presence of the commercial antiEtag antibody (Etag) and exposed to film. A signal corresponding to a single predominant polypeptide is evident in the mosquito extracts derived from N2scFv and 4GscFv-expressing mosquitoes and is not present in the controls (NoSin). The locations of molecular weight markers are shown to the right of the figure. C) Immunodetection of N2scFv binding to sporozoites in vivo. Sporozoites were recovered from the hemolymph of Plasmodium gallinaceuminfected mosquitoes that had been injected with SinN2scFv or a control virus, SinEGFP. Sporozoites were incubated with the E-tag antibody and fluoroscein-conjugated secondary antibody, and examined using Phase contrast or Fluorescence microscopy. Only sporozoites exposed to N2scFv react with the appropriate antibody. GGACTAACCACCGGGTTGGACTGGTGGGAAGAGGT-GAAACTGCAGCAGTC-3Ј, and Primer 5) 5Ј-GGCA-C G C G G T T C C A G C G G AT C C G G AT A C G G C A -CCGGCGCTCCGCCTGCAGGTCGTCC-3Ј. In the first reaction, Primers 4 and 5 were used to amplify the 4G2scFv construct. These primers include the E-tag sequences and a portion of the Mal I fragment. Subsequent amplification with Primers 2 and 3 completed the construct. As before, all amplification products were sequenced to verify primary structure.
Production of infectious virus has been described. 19, 27, 28 Viruses were harvested and aliquots stored at Ϫ70ЊC until used. Aliquots of viruses were titrated in BHK-21 cells using an end-point assay. 19, 29 Salivary gland infection assays. Approximately 0.5 L of a solution containing 1 ϫ 10 7 TCID 50/ml SinN2scFv were injected intrathoracically into 2-3 day-old adult, female mosquitoes. Mosquitoes were incubated for two days following injections and then allowed to feed for 15 min on P. gallinaceum-infected chickens. Only females that had fed to repletion were used in the experiments. Midguts were dissected from mosquitoes 8-9 days after parasite infection and examined microscopically to determine oocyst prevalence and mean intensity of infection. Salivary gland pairs were dissected from individual mosquitoes 12-14 days after parasite infection and homogenized in 10 L PBS. The wholesalivary-gland homogenate was placed on a hemacytometer, and the sporozoites counted using phase-contrast microscopy. This procedure allowed the examination of the whole salivary gland for sporozoites. All fields of the hemacytometer were examined thoroughly and counted in samples with low parasite densities, and five fields were averaged with samples having high parasite densities. Control mosquitoes included parasite-infected groups that were not injected with a virus (NoSin), groups that were injected with a virus expressing the EGFP (SinEGFP), 29 and groups that were infected with a virus expressing the antidengue 4G2scFv (Sin4G2scFv). AA, unpublished data). We determined next whether N2scFv cloned into a Sindbis virus construct was expressed in mosquitoes and bound sporozoites in situ. SinN2scFv was injected into adult female mosquitoes ( Figure 1A) . Control mosquitoes were untreated or injected with either SinEGFP or Sin4G2scFv. Whole mosquitoes were homogenized 10 days after viral infection, and the homogenates resolved by SDS-PAGE and analyzed on immunoblots ( Figure 1B) . Proteins of the predicted molecular weights, ϳ30 kiloDaltons (kDa) for N2scFv and ϳ29 kDa for 4G2scFv, were detected in only those mosquitoes infected with SinN2scFv or Sin4G2scFv, respectively. These results demonstrated that the scFvs were expressed in the mosquito. Additional experiments were conducted to determine if the expressed N2scFv bound sporozoites ( Figure 1C ). Following infection by SinN2scFv or control viruses, and a blood meal from a parasite-infected chicken, parasites were recovered from the hemolymph and reacted with the E-tag antibody. Only those parasites from mosquitoes expressing N2scFv reacted with the E-tag antibody. These results demonstrated that N2scFv was produced as a result of viral ex-pression in the mosquitoes and that the expressed recombinant antibody reacted with sporozoites in vivo.
RESULTS

Sindbis virus-mediated expression of N2scFv in mosquitoes. Immunoblot analyses demonstrated that recombinant N2scFv bound to CSP (de Lara Capurro M and James
N2scFv blocks sporozoite infection of salivary glands. A series of nine experiments were performed to determine if Sindbis virus-expressed N2scFv could block sporozoite infection of salivary glands ( Table 1 ). The number of oocysts were estimated or counted to provide an initial indication of the intensity of infection in a specific experiment. Mosquitoes in Experiments 1-4 were estimated to have high oocyst intensities of infection, greater than 15 oocysts/midgut, and SinEGFP-infected and NoSin mosquitoes were used as controls. The mosquitoes in Experiments 5 and 6 had lower oocyst intensities, and again the controls were either Sin-EGFP-infected or NoSin mosquitoes. The mosquitoes in Experiments 7-9 had variable oocyst intensities of infections, and the controls used were NoSin and Sin4G2scFv-infected mosquitoes.
Injections of virus in Experiments 1-6 had no effect on oocyst prevalence or mean intensity of infection. However, Sin4G2scFv-infected mosquitoes (Experiments 7-9) showed a consistent reduction in oocyst mean intensities when com- 1-10, 11-100, 101-1000, and Ͼ1000 , and the percentage of the total in each class determined. The number of mosquitoes in each category is listed above each histogram. The total number of mosquitoes in each group is listed in parentheses adjacent to the key. NoSin, SinEGFP, Sin4G2scFv, and SinN2scFv are defined in the text. pared to NoSin controls. It appeared that virus infection did not affect the prevalence of sporozoite infections in salivary glands in any of the experiments. It is important to emphasize that prevalence was determined by including salivary gland pairs that were infected by as few as one sporozoite. In all experiments, control viruses reduced by about one-half the sporozoite intensity of infections in salivary glands. In contrast, mean intensities of sporozoites in salivary glands from SinN2scFv-infected mosquitoes were reduced by at least 96.8% in all experiments, and in one, Experiment 7, sporozoites were reduced by 99.9% when compared to virusinfected controls.
A histogram that represents the percentage of mosquitoes in each treatment group from all experiments that had a particular level of infection is shown in Figure 2 . These data show that 53% (54/102) of the pairs of salivary glands recovered from SinN2scFv-infected mosquitoes had 10 or fewer sporozoites while less than 14% (31/228) of the mosquitoes in the combined control groups had similar values. Furthermore, a total of 84% (86/102) of the salivary gland pairs from the SinN2scFv group had 100 or fewer parasites, and this value contrasts remarkably with those obtained for the same respective infection ranges in the NoSin, 8.4% (9/108), SinEGFP, 22% (20/90), and Sin4G2scFv, 10% (3/30), groups. Parasite intensities of 1,000 or more sporozoites in salivary glands were observed in 72-90% of control mosquitoes and in only 4% of those infected with SinN2scFv.
DISCUSSION
The binding of Sindbis virus-expressed N2scFv to sporozoites in vivo demonstrates its potential as an effector portion of an antiparasite gene. The blocking experiments show that N2scFv functions as an antiparasite effector molecule. Experiments 1-4 were performed with mosquitoes that had high oocyst intensities of infection. While no effect on prevalence was evident, a strong effect of the presence of N2scFv on mean intensity of infections in salivary glands was observed. We adjusted the mosquito feeding regime in Experiments 5 and 6 to yield midguts with lower oocyst infections in anticipation of affecting salivary gland prevalence and lowering further the mean intensities. However, we were unable to get a consistent effect on prevalence and the mean intensities, although low, were not zero. This observation most likely results from differences in the Sindbis virus infections and therefore the level of N2scFv expressed in individual mosquitoes. Some mosquitoes may not have been infected following viral inoculation, while others may not have propagated the virus to a high titer. Mosquitoes in which the Sindbis infection is robust should produce high levels of N2scFv and this should result in no or few parasites in the salivary glands. In contrast, those mosquitoes with no or a low titer virus infection should result in high numbers of parasites in their glands. The distribution of the data plotted in Figure 2 is consistent with this interpretation. However, it is important to emphasize that the overall effect of N2scFv was to reduce substantially the mean intensities of sporozoite infections of salivary glands.
Mean intensities of sporozoite infections in virus-expressing control mosquitoes (SinEGFP or Sin4G2scFv) were about half of those observed in the corresponding NoSin controls. In addition, virus infection had an effect on the mean intensity of oocysts in Sin4G2scFv-infected mosquitoes. We interpret these results to be due to the cytopathological effects of the virus expression. Damage to cells in the midguts and salivary glands may account for these differences.
Experiments 1-6 used SinEGFP-infected mosquitoes as negative controls. The structure of this construct lacks the Mal I secretory leader peptide and E-tag sequences. Therefore, for Experiments 7-9, we used Sin4G2scFv as a control. No consistent differences in percent reduction in mean intensities of salivary gland infections among controls were observed indicating that the leader peptide and E-tag sequences played no role in the blocking properties of N2scFv.
The data presented here cannot be used to determine the level of sporozoite blocking that is required to interrupt parasite transmission. Estimates vary as to the minimum sporozoite inoculum required during a natural infection cycle to establish an infection in a host. For some Plasmodium species, 10 or fewer sporozoites may be sufficient. 30 However, a reliable correlation has not been established between the mean intensity of infection in salivary glands and the number of sporozoites inoculated during feeding. Although we have achieved reduction of the mean intensities to 100 or fewer parasites per gland for 84% of the N2scFv-expressing mosquitoes, 16% of the mosquitoes have greater than this amount and these are sufficient to transmit parasites to the vertebrate host (de Lara Capurro M and James AA, unpub-lished data). We conclude that although the Sindbis expression system allows testing the potential of an antiparasite effector molecule, because of its variability in infection, it is not adequate to test transmission blocking. Stable, transgenic lines expressing N2scFv will be needed to do the latter experiments. Individual transformed lines should express N2scFv at a constant level (depending on the promoter used to drive the expression of the construct and the site of genome integration), and parasite intensity of infection can be measured as a function of the level of N2scFv present.
We do not know the mode of action of N2scFv that is responsible for the reduction of the mean intensity of sporozoite infections in the salivary glands. Although domain I of the CSP has been shown to be important in binding of Plasmodium falciparum to Anopheles stephensi salivary glands, 31 the repeat region of P. gallinaceum CSP, to which the parental N2H6D5 MAb binds, 17 has yet to be shown to be a true ligand domain. Binding of N2scFv to CSP may interfere with other receptor-ligand interactions and prevent the parasite from contacting the salivary gland. Alternately, N2scFv may immobilize or kill sporozoites in some manner that remains to be determined. However, it is evident from the data presented here and other published blocking data [14] [15] [16] that the repeat region can be targeted to interrupt parasite transmission.
A number of proteins have been tested as potential effector molecules for engineered antiparasite genes. Insect defensins, 32 magainins and cecropin-like molecules, 33, 34 and scorpion toxins 35 all have been shown to kill malaria parasites. An scFv that targets the Plasmodium berghei ookinete protein, Pbs21, blocks oocyst development in the mosquito if the recombinant antibody is injected into a mouse host and is ingested by the mosquito along with the parasite. 36 These and similar molecules may be used in conjunction with scFvs like N2scFv to introduce into mosquitoes a synthetic, multifunctional antiparasite gene that may prevent resistance mechanisms from developing rapidly in the parasites. Of course, application of these developments to P. falciparum and Plasmodium vivax is the ultimate goal, and we anticipate that these results along with those of other investigators will encourage research in these important human pathogens and their vectors.
